Opexa Therapeutics (OPXA) – Analyst PT Change
-
Aegis Capital Boosts PT on Opexa Therapeutics (OPXA) to $11 Ahead of Abili-T Phase IIb Data
-
Aegis Capital Restarts Opexa Therapeutics (OPXA) at Buy; Bullish on Secondary Progressive MS Progress
Back to OPXA Stock Lookup